ArticleActa neurologica Belgica2026
Long-term efficacy and predictors of response to greater occipital nerve pulsed radiofrequency in migraine with prior preventive treatment failure.
Article in Acta neurologica Belgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMigraine with prior preventive treatment failure represents a significant clinical challenge. While Greater Occipital Nerve (GON) Pulsed Radiofrequency (PRF) is a promising intervention, data regarding its long-term efficacy are limited. This study aimed to evaluate the one-year efficacy of ultrasound-guided GON PRF in this patient population and to identify predictors of a sustained clinical response.
methodsThis retrospective cohort study included 116 adults with migraine and prior preventive treatment failure. The primary endpoint was achievement of the Patient Acceptable Symptom State (PASS) at 12 months, which defined responders. Secondary endpoints included changes in monthly headache days (MHDs), visual analog scale (VAS) scores, patient-perceived improvement assessed using the 7-point Global Perceived Effect (GPE) scale, and treatment durability assessed by Kaplan-Meier analysis. Predictors of response were explored using multivariable logistic regression.
resultsAt 12 months, 70 of 116 patients (60.3%) achieved the PASS and were classified as responders. Significant reductions were achieved in mean MHDs (from 14.3 to 6.1, p < 0.001) and mean VAS scores (from 6.6 to 5.6, p < 0.05). Kaplan-Meier analysis estimated a 60.3% probability of sustained benefit at one year. Overall, 53.4% of patients reported > 75% improvement on the GPE scale. A strong clinical response at one month was significantly associated with one-year success. Higher baseline mean VAS score was the only independent predictor of long-term success (OR: 1.62).
conclusionGON PRF provides significant and durable clinical benefits for patients with migraine and prior preventive treatment failure. This minimally invasive procedure may represent an effective long-term therapeutic option, and a positive early response may predict sustained clinical success.
Indexed as
Identifiers
42631838What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.